Management of Hemophilia with Minimal Factor Replacement in Developing Countries: Role of Ancillary Therapy

ABSTRACT

Compared with developed countries, the care of hemophiliacs in still relatively poor in developing countries. There are three major factors that influence this problem: inadequate knowledge, lack of laboratories to diagnose the disorder, and inadequate supply of factor concentrates. It is important that healthcare providers and family members of these patients be adequately educated about all of the aspects of hemophilia. Basic laboratories could be established at a reasonable price, technical personnel could be trained, and quality-assurance programs could be initiated. Even in the absence of high-quality factor concentrates, which are expensive, there are affordable means to manage these patients, although certainly not optimally. To overcome these problems, hemophilia care services need to be established and integrated to facilitate the basic needs for these patients.

KEYWORDS

Hemophilia - diagnosis - treatment - education - adjuvant treatment modalities

REFERENCES

• 1 Lofqvist T, Nilsson I M, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long term follow-up.  J Intern Med. 1997;  241 395-400
• 2 World Population Data Sheet .New York; The Population Reference Bureau 2003
• 3 Soucie J, Soucie M, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System.  Am J Hematol. 1998;  59 288-294
• 4 Report on the WHO Global Survey 2003 .Montreal, Canada; World Federation of Haemophilia 2004
• 5 WHO Country Report. India .http://www.who.int/country/en Accessed November 2004
• 6 Union Budget 2002-2003: Government of India .Ministry of Finance. http://Indiabudget.nic.in Accessed November 2004
• 7 Chandy M Report of the Collaborative Study on Haemophilia. New Delhi, India; Indian Council of Medical Research 1991
• 8 Jayandharan G, Shaji R V, Chandy M, Srivastava A. Identification of factor IX gene defects using a multiplex PCR and CSGE strategy-a first report.  J Thromb Haemost. 2003;  1 2051-2054
• 9 Deal D N, Tipton J, Rosencrance E, Curl W W, Smith T L. Ice reduces edema: A study of microvascular permeability in rats.  J Bone Joint Surg Am. 2002;  84 1573-1578
• 10 Mac Auley D C. Ice therapy: how good is the evidence?.  Int J Sports Med. 2001;  22 379-384
• 11 Weiss A E. Doses of factor VIII for hemophilic bleeding.  N Engl J Med. 1977;  297 1237-1238
• 12 Sindet-Pederson S. Distribution of tranexamic acid in plasma and saliva after oral administration and mouth rinsing-a pharmacokinetic study.  J Clin Pharmacol. 1987;  27 1005-1008
• 13 Sindet-Pedersen S, Ramstrom G, Bernvil S, Blombäck M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant treated patients undergoing oral surgery.  N Engl J Med. 1989;  320 840-843
• 14 Zanon E, Martinelli F, Bacci C, Zerbinati P, Girolami A. Proposal of a standard approach to dental extraction in haemophilia patients. A case-control study with good results.  Haemophilia. 2000;  6 533-536
• 15 Isarangkura P, Chiewsilp P, Chuansumrit A et al.. Low cost locally prepared fibrin glue for clinical applications: reported of 145 cases. Committee of Bangkok International Hemophilia Training Center.  J Med Assoc Thai. 1999;  82(suppl 1) S49-S56
• 16 Rakocz M, Mazar A, Varon D, Spierer S, Blinder D, Martinowitz U. Dental extractions in patients with bleeding disorders. The use of fibrin glue.  Oral Surg Oral Med Oral Pathol. 1993;  7 280-282
• 17 Martinowitz U, Schulman S. Fibrin sealant in surgery of patients with a hemorrhagic diathesis.  Thromb Haemost. 1995;  74 486-492
• 18 Lethagen S. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety.  Semin Thromb Hemost. 2003;  29 101-106
• 19 Leissinger C, Becton D, Cornell Jr C, CoxGill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia.  Haemophilia. 2001;  7 258-266
• 20 Favaloro E J, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies.  Haemophilia. 2001;  7 180-189
• 21 Srivastava A, Chandy M, Sunderaj G D et al.. Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia.  Haemophilia. 1998;  4 799-801
• 22 Gralnick H R, Rick M E. Danazol increases factor VIII and IX in classical hemophilia and Christmas disease.  N Engl J Med. 1983;  308 1393-1395
• 23 Sommer S S, Hill K A, Ewing N, High K, Peltz S, Zaia J. Translational bypass therapy. Presented at: 6th Gene Therapy Workshop April 26, 2003 The Salk Institute for Biological Studies La Jolla, CA;
• 24 Lillicrap D, James P, Poon M-C, Rivard G. Suppression of nonsense mutations in severe hemophilia A and B. Presented at: 6th Gene Therapy Workshop April 26, 2003 The Salk Institute for Biological Studies La Jolla, CA;
• 25 Chandy M, Khanduri U, Dennison D. Developing hemophilia services in India.  Southeast Asian J Trop Med Pubic Health. 1993;  24(suppl 1) 66-68
• 26 Chandy M. Management of haemophilia in developing countries with available resources.  Haemophilia. 1995;  1(suppl 1) 44-48